Stock Symbol:
IMRA
Case Status:
Investigations
Ademi LLP is investigating Imara (Nasdaq: IMRA) for possible breaches of fiduciary duty and other violations of law in its transaction with Enliven.
Ademi LLP alleges Imara’s financial outlook and prospects are excellent and yet Imara holders will receive only approximately 14% of the combined company. The transaction agreement unreasonably limits competing bids for Imara by imposing a significant penalty if Imara accepts a superior bid. Imara insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Imara’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Imara.